Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
135 studies found for:    INCB018424
Show Display Options
Rank Status Study
21 Not yet recruiting Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
Condition: Essential Thrombocythemia
Interventions: Drug: Ruxolitinib;   Drug: Anagrelide;   Drug: Placebo
22 Available An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Condition: Graft-versus-host Disease (GVHD)
Intervention: Drug: Ruxolitinib
23 Recruiting A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
24 Active, not recruiting Topical Ruxolitinib for the Treatment of Vitiligo
Condition: Vitiligo
Intervention: Drug: Ruxolitinib 1.5% Phosphate Cream
25 Recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC)
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
26 Not yet recruiting A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Condition: Graft-versus-host Disease
Interventions: Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib
27 Recruiting Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
28 Recruiting A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Condition: Graft-versus-host Disease
Interventions: Drug: Ruxolitinib;   Drug: Prednisone or methylprednisolone
29 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
30 Not yet recruiting Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: ruxolitinib;   Drug: ibrutinib
31 Not yet recruiting Ruxolitinib for Premalignant Breast Disease
Conditions: Ductal Carcinoma In Situ;   Atypical Lobular Hyperplasia;   Atypical Ductal Hyperplasia;   Lobular Carcinoma In Situ
Interventions: Drug: Ruxolitinib;   Drug: Placebo (for Ruxolitinib)
32 Active, not recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
33 Recruiting TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Conditions: Myelofibrosis;   Polycythemia Vera
Interventions: Drug: TGR-1202;   Drug: ruxolitinib
34 Recruiting Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   PMF;   SMF;   Post-PV MF;   Post-ET MF
Intervention: Drug: INCB018424/CC-4047
35 Active, not recruiting Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Pracinostat;   Behavioral: Questionnaire
36 Active, not recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
37 Completed Phase l/II Study of Ruxolitinib for Acute Leukemia
Condition: Leukemia
Intervention: Drug: Ruxolitinib
38 Active, not recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
39 Recruiting Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
40 Active, not recruiting Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Conditions: Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.